Atara Falls As PINTA Sinks In Phase II
This article was originally published in Scrip
Executive Summary
Atara Biotherapeutics Inc. fell 36.8% to $21 per share on Dec. 14 after the company suspended work on PINTA 745 for the reversal of peptide-energy wasting (PEW), leaving only two of the company's Christopher Columbus-themed drug candidates – previously in development by subsidiaries known as Nina and Santa Maria – afloat along with newer oncology and immunotherapy programs.